EpiVax, Inc. - Informatics and Immunology
  • Our Company
    • Company Overview
    • Corporate Responsibility
    • Mission, Vision & Values
    • Team
    • Careers
    • Contact Us
  • Pipeline
    • Pipeline Overview
    • BioDefense Vaccines
    • Tregitope: Immunomodulation Power Tool
    • Deimmunization Projects
  • Vaccine Services
    • Vaccine Services
    • iVAX: Web-based Vaccine Design
    • PreVAX Analysis
    • EpiCC
  • Immunogenicity Assessment
    • Immunogenicity Assessment Overview
    • ISPRI Web-based Immunogenicity Assessment
    • PreDeFT Analysis
    • High Throughput Immunogenicity Analysis
    • PANDA Screening
    • ISPRI for Host Cell Proteins
    • Deimmunization
    • Trusted Expert Advice (TEA) Consulting Services
  • Lab Services
    • Lab Services Overview
    • HLA Binding Assays
    • T Cell Assays
  • Press Room
    • Press Room
    • Events
      • Webinars
    • Publication & Poster Search
    • Client Testimonials
    • Thinking Out Loud (Blog)
    • Recipes For Success (Podcast)
  • Contact Us
Select Page
Innovative preclinical assessment tools for safety and efficacy of protein and peptide therapeutics… Of Peptides and P-ANDAS

Innovative preclinical assessment tools for safety and efficacy of protein and peptide therapeutics… Of Peptides and P-ANDAS

by Elena Iemma | Sep 22, 2023

Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics… of Peptides and P-ANDAS
Immunogenicity risk assessment of synthetic peptide drugs and their impurities

Immunogenicity risk assessment of synthetic peptide drugs and their impurities

by Elena Iemma | Jul 27, 2023

Immunogenicity risk assessment of synthetic peptide drugs and their impurities – ScienceDirect
In silico immunogenicity assessment for sequences containing unnatural amino acids: A method using existing in silico algorithm infrastructure and a vision for future enhancements

In silico immunogenicity assessment for sequences containing unnatural amino acids: A method using existing in silico algorithm infrastructure and a vision for future enhancements

by Riley Nolan | Oct 11, 2022

Addressing Immunogenicity of Observed and Theoretical Impurities for Peptide Abbreviated New Drug Applications

Addressing Immunogenicity of Observed and Theoretical Impurities for Peptide Abbreviated New Drug Applications

by Annie De Groot | Sep 23, 2020

Addressing Immunogenicity of Observed and Theoretical Impurities for Peptide Abbreviated New Drug Applications
Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics … Of Peptides and P-ANDAS A Case Study of Taspoglutide

Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide Therapeutics … Of Peptides and P-ANDAS A Case Study of Taspoglutide

by Annie De Groot | Sep 9, 2019

EpiVax_PANDA_Taspoglutide_April_19_Final
« Older Entries

Recent Posts

  • Hey Hey! Hallo! This is a two-way conversation!
  • EpiVax CEO Speaks at the Hwasun International Vaccine and Immunotherapy Forum
  • Visits from the FBI and SEC… and Fearless Science
  • Dreaming of Peptides (and Hello from Tokyo!)
  • Streamlining Generic Drug Immunogenicity Evaluation: EpiVax’s “PANDA” Approach

Categories

  • EpiVax Immunoncology
  • Events
  • Featured
  • News
  • Recipes for Success – Vlog
  • Thinking Out Loud -Blog
  • Uncategorized
  • Webinars

Discover

  • Vaccine Services
  • Immunogenicity Assessment
  • Deimmunization
  • Lab Services
  • Pipeline

About

  • Our Company
  • Press Room
  • Events
  • Publication & Poster Search
  • Thinking Out Loud (Blog)
  • Contact Us

Connect

© 2023 EpiVax, Inc. – Informatics and Immunology, All rights reserved. Privacy Policy • 188 Valley Street, Suite 424, Providence, RI 02909 • ph: 401.272.2123 • fax: 401.272.7562